体外
纤维
化学
多巴胺
细胞毒性
蛋白质聚集
共核细胞病
淀粉样蛋白(真菌学)
生物物理学
小分子
生物化学
β淀粉样蛋白
刚果红
血脑屏障
α-突触核蛋白
帕金森病
生物
肽
神经科学
医学
中枢神经系统
疾病
无机化学
病理
有机化学
吸附
作者
Ashim Paul,Adi Huber,Daniel Rand,Fabien Gosselet,Itzik Cooper,Ehud Gazit,Daniel Segal
标识
DOI:10.1002/chem.202003374
摘要
Abstract Accumulation and aggregation of the intrinsically disordered protein α‐synuclein (α‐Syn) into amyloid fibrils are hallmarks of a series of heterogeneous neurodegenerative disorders, known as synucleinopathies and most notably Parkinson's disease (PD). The crucial role of α‐Syn aggregation in PD makes it an attractive target for the development of disease‐modifying therapeutics that would inhibit α‐Syn aggregation or disrupt its preformed fibrillar assemblies. To this end, we have designed and synthesized two naphthoquinone–dopamine‐based hybrid small molecules, NQDA and Cl‐NQDA, and demonstrated their ability to inhibit in vitro amyloid formation by α‐Syn using ThT assay, CD, TEM, and Congo red birefringence. Moreover, these hybrid molecules efficiently disassembled preformed fibrils of α‐Syn into nontoxic species, as evident from LUV leakage assay. NQDA and Cl‐NQDA were found to have low cytotoxicity and they attenuated the toxicity induced by α‐Syn towards SH‐SY5Y neuroblastoma cells. NQDA was found to efficiently cross an in vitro human blood–brain barrier model. These naphthoquinone–dopamine based derivatives can be an attractive scaffold for therapeutic design towards PD.
科研通智能强力驱动
Strongly Powered by AbleSci AI